2. Academic Validation
  3. Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors

Sporadic cefiderocol resistance in Escherichia coli from the United Arab Emirates involves multifactorial mechanisms reversible by novel beta-lactamase inhibitors

  • Sci Rep. 2025 Sep 29;15(1):33616. doi: 10.1038/s41598-025-19084-6.
Farah Al-Marzooq 1,  Hafsa Ahli 2,  Rauda Aldhaheri 2,  Omar Aleissaee 2,  Abdulrahman Alzaabi 2,  Abdullah Alsaadi 2,  Hamad Almansoori 2,  Akela Ghazawi 2,  Lana Daoud 2,  Amna Ahmad 2,  Timothy Collyns 3
Affiliations

Affiliations

  • 1 Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box No. 15551, Al Ain, United Arab Emirates. f.almarzooq@uaeu.ac.ae.
  • 2 Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, P.O. Box No. 15551, Al Ain, United Arab Emirates.
  • 3 Tawam Hospital, Al Ain, United Arab Emirates.
PMID: 41023121 DOI: 10.1038/s41598-025-19084-6
Abstract

Cefiderocol (CFDC), a novel siderophore-cephalosporin, is effective against multidrug-resistant (MDR) pathogens, but the emergence of resistance threatens its future use in treating infections. This study reports the emergence of CFDC resistance in four E. coli strains isolated from immunocompromised and critically ill patients in the United Arab Emirates, and provides a comprehensive genomic analysis of these strains, aiming to uncover the mechanisms driving this resistance. Whole-genome Sequencing with bioinformatic analysis revealed specific Beta-lactamase variants (NDM-5, CMY-2/145, and OXA-181) and unique mutations in siderophore-iron transport genes (cirA, fepA, fecA, fiu, and tonB) and penicillin-binding proteins (PBPs) associated with resistance. Phylogenetic analysis showed that the strains were not clonally related, indicating the sporadic nature of resistance. To address this challenge, we evaluated the efficacy of several novel Beta-lactamase inhibitors (BLIs) combined with CFDC. In vitro susceptibility testing demonstrated that these inhibitors restored the Antibacterial activity of CFDC against resistant strains. Zidebactam, with intrinsic Antibacterial activity, caused the most significant reduction in CFDC minimum inhibitory concentrations (MICs), while the activity of Other inhibitors (taniborbactam and xeruborbactam) was dependent on the genetic makeup of the strains, especially mutations in the siderophore-iron uptake genes. Our findings underscore the importance of genomic surveillance in deciphering Antibiotic resistance mechanisms. Novel BLIs and partner Antibiotics could be added weapons in the fight against MDR bacteria; thus, we recommend using combinations with novel BLIs as innovative therapeutic options to combat the emerging threat of CFDC resistance, after proper validation of their in vivo efficacy.

Keywords

Escherichia coli; Beta-lactamase inhibitors; Cefiderocol; Whole-genome sequencing.

Figures
Products